Global X FTSE Southeast Asia ETF vs Cardinal Health Inc — how do they compare? Global X FTSE Southeast Asia ETF trades at $21.43, while Cardinal Health Inc trades at $234.16 (market cap $55.88B). The key difference: Cardinal Health Inc pays a 0.86% dividend while Global X FTSE Southeast Asia ETF pays none. Which is the better fit depends on your goals.
| ASEA | CAH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $21.53 | $240.26 |
52-Week Low | $16.86 | $146.04 |
Market Cap | — | $55.88B |
Enterprise Value | — | $59.91B |
Dividend Yield | — | 0.86% |
Signals from Pluang's Aura AI — not financial advice
ASEA stock trades at $21.45 with a modest 0.23% daily gain, showing bullish technical momentum with strong moving average support. The company has announced a $0.41 dividend for H1-2026, indicating management confidence in cash flow stability. Technical indicators show the stock is approaching resistance at $22 with strong trend momentum.
The stock presents a bullish technical setup near key resistance levels, though fundamental data remains limited. Dividend payments provide income appeal, but investors require updated financial metrics for comprehensive valuation assessment. Near-term price action will test the $22 resistance zone.
Cardinal Health (CAH) trades at $235.3, down 0.79% on the day, but remains near its 52-week high. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue for fiscal 2025 was $222.58 billion, with net income reaching $1.56 billion. Analyst consensus is strongly positive, with 18 buys and a $266.43 price target, reflecting confidence in the company's pharmaceutical and specialty business growth.
The outlook for CAH is favorable, driven by robust earnings performance and optimistic fiscal 2027 guidance. Key opportunities include sustained demand for specialty drugs and operational efficiency gains. Risks involve high debt levels, with a debt-to-asset ratio of 16.09 in 2025, and competitive pressures in the healthcare distribution sector. Investors should weigh strong analyst support against balance sheet leverage and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →